TABLE A4.
Concomitant Anticoagulants
| Anticoagulant Use | Subcutaneous Group (n = 206), No. (%) | Intravenous Group (n = 210), No. (%) |
|---|---|---|
| Patients with one or more concomitant anticoagulants | 164 (80) | 171 (81) |
| Antithrombotic agents | ||
| Direct factor Xa inhibitors | 132 (64) | 143 (68) |
| Rivaroxaban | 89 (43) | 76 (36) |
| Apixaban | 38 (18) | 54 (26) |
| Edoxaban | 7 (3) | 17 (8) |
| Heparin group | 48 (23) | 45 (21) |
| Enoxaparin | 39 (19) | 35 (17) |
| Heparin | 4 (2) | 2 (1) |
| Tinzaparin | 3 (2) | 2 (1) |
| Low molecular weight heparin | 3 (2) | 1 (0.5) |
| Bemiparin | 2 (1) | 3 (1) |
| Nadroparin | 1 (0.5) | 2 (1) |
| Dalteparin | 0 | 1 (0.5) |
| Other antithrombotic agents | 1 (0.5) | 3 (1) |
| Fondaparinux | 1 (0.5) | 3 (1) |
| Direct thrombin inhibitors | 0 | 1 (0.5) |
| Dabigatran | 0 | 1 (0.5) |
| Vitamin K antagonists | 0 | 1 (0.5) |
| Warfarin | 0 | 1 (0.5) |